The Weekly Recap 10/16/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, achieve regulatory approvals, appoint new executives, launch partnerships, and much more on the road to LSI USA ‘27 in Dana Point (March 15 - 19).

Abram Scientific

Awarded a DARPA contract worth up to $8.3M to advance its CoagCare™ rapid, handheld blood coagulation testing platform for trauma settings, following a previous $2M DARPA contract in October 2025. The point-of-care system uses a compact meter and single-use diagnostic card to assess whole-blood clot formation and breakdown in under 10 minutes, providing actionable information to help identify coagulation abnormalities and guide treatment.

Butterfly Medical

Received EU Medical Device Regulation certification for its Butterfly Prostatic Retraction Device, an anatomically designed implant intended to relieve urinary symptoms associated with BPH. The device aims to improve urinary flow without cutting, burning, or removing tissue, offering an alternative between pharmaceutical therapies and invasive surgery without requiring dedicated capital equipment. 

CMR Surgical

Received a strategic equity investment of approximately $400M (£300M) from Stryker, including an exclusive option for Stryker to acquire the remaining equity of CMR Surgical and an exclusive U.S. commercial agency agreement for the Versius portfolio. The partnership combines CMR Surgical’s soft-tissue robotics portfolio and clinical expertise with Stryker’s commercial reach, with Stryker leading U.S. sales and CMR Surgical continuing portfolio development and commercialization outside the U.S.

DeepSight Technology

Appointed LSI Alumni Scott Huennekens to its Board of Directors. Huennekens brings decades of experience building and scaling medical technology companies, with a track record spanning image-guided therapy, surgical robotics, and digital surgery.

E2 - Endovascular Engineering

Received dual FDA 510(k) clearances for the Hēlo^® Thrombectomy System and Hēlo^® Blood Return System for treating pulmonary embolism and removing clots from peripheral veins. The Hēlo® platform is designed to support effective clot removal during thrombectomy procedures while returning high-quality aspirated blood to the patient.

Elevage Medical Technologies

Appointed LSI Alumni Michael Wasserman as CEO. Wasserman joined the company as Partner and COO, and will look to advance the company’s mission to partner with innovative healthcare companies. 

EndoQuest Robotics

Appointed Jared Eben as Chief Clinical Officer. Eben brings nearly two decades of experience across surgical robotics, digital surgery, operating room integration, and healthcare technology commercialization.

Epitel

Appointed Melissa Farina as CFO. Farina brings more than 20 years of finance leadership experience across public and private medical device companies, with a track record spanning financial strategy, capital allocation, M&A, and commercial growth.

iSono Health

Appointed Dr. Said Bolorforosh to its Board of Directors, bringing more than 30 years of experience developing diagnostic medical ultrasound products and leading medtech innovation. Dr. Bolorforosh previously held senior leadership roles at ACUSON, GE HealthCare, Siemens Healthineers, Haemonetics, and Medtronic Diabetes, including serving as President of Siemens Ultrasound and EVP and CTO at Haemonetics.

Minze Health

Achieved ISO 27001 certification. The medical device and digital health company aims to combine at-home uroflowmetry (Homeflow), automated bladder diary monitoring, and a digital therapeutic for BPH (Lutastic+) into a single connected platform, with its Minze app driving strong patient engagement through symptom tracking (IPSS, OABSS, voids, fluid intake).

Nami Surgical

Secured £3.4M in a funding round extension, including a £2M investment from the Scottish National Investment Bank, with continued backing from existing investors Eos Advisory, Scottish Enterprise, and the Investment Fund for Scotland. The funding will support commercialization and expansion of the research and development team.

OrisDX

Announced a strategic partnership with the ADA Forsyth Institute to bridge dental care and precision medicine through saliva-based molecular diagnostics. The collaboration will generate longitudinal clinical evidence and develop evidence-based education for dental professionals on emerging technologies, including genomic testing, biomedical imaging, innovative therapeutics, and next-generation diagnostics.

Panakès Partners

Raised €8.5M through Lombardia Venture STEP, a venture capital fund of funds promoted by Regione Lombardia and managed by Finlombarda. The funding will enable Panakès to co-invest alongside its main funds in innovative medtech and biotech startups and scaleups in Lombardy, strengthening the region’s life sciences innovation ecosystem.

Precision Life Science Partners

Announced a strategic partnership with AO Technology AG, part of the AO Foundation, to help advance early-stage orthopedic and musculoskeletal technologies from proof of concept through Series A. The partnership will combine the AO Foundation’s global surgeon network and clinical expertise with structured technology evaluation, early clinical validation, due diligence, and commercial strategy.

Sentante

Received FDA 510(k) clearance for its digital indeflator, Inflante. Inflante is a precision-controlled digital indeflator designed to modernise balloon inflation, improve clinical control, and improve procedural consistency by contributing pressure profiles, inflation timing, and procedural state to the multi-modal data layer that the broader Sentante robotic platform records. 

Spiro Medical

Treated the first patient in the PULSAR feasibility study evaluating its investigational treatment for severe, uncontrolled asthma. The FDA-approved IDE study will enroll up to 30 patients across multiple U.S. centers, targeting those whose asthma remains uncontrolled despite optimal pharmacological or biologic therapy.

Stratus & Zeto

Announced a strategic partnership to expand hospital access to point-of-care EEG through an exclusive distribution agreement for Zeto ONE™. The partnership combines Zeto’s FDA-cleared, rapid-application full-montage EEG technology with Stratus’ nationwide network of registered EEG technologists providing 24/7 remote monitoring and technical oversight.

THINK Surgical & Zimmer Biomet

Announced a multi-year extension of its Limited Exclusive Distribution and Supply Agreement. Under the extension, Zimmer Biomet will continue distributing an exclusive version of THINK Surgical’s wireless, handheld TMINI Miniature Robotic System, compatible with its Persona Knee System.

Vantis Vascular

Received FDA 510(k) clearance for a new 6 French (6F) model of its CrossFAST^® Integrated Microcatheter Advanced Delivery System. The updated model features a larger lumen to accommodate a broader range of interventional devices and a shorter distal tip designed for complex percutaneous coronary intervention (PCI) procedures.

XCath Robotics

Accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot for the Iris Surgical Robotic System, designed for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. Following its Breakthrough Device Designation in September 2026, TAP enrollment provides the company with opportunities for ongoing strategic engagement with the FDA throughout development.

Xeltis

Appointed Remco Jansen as Vice President of Clinical Development. Jansen brings more than 20 years of experience across cardiovascular and vascular therapies, clinical strategy, and physician education, including 15 years at Getinge and previous roles at Convatec and AstraZeneca.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.